Education
About Us
Working with TipRanks
Follow Us
Sinco Pharmaceuticals Holdings Ltd. (HK:6833)
:6833
6833 Stock Chart & Stats
HK$0.18
HK$0.02(7.44%)
At close: 4:00 PM EST
HK$0.18
HK$0.02(7.44%)
Day’s Range― - ―
52-Week RangeHK$0.15 - HK$0.28
Previous CloseN/A
Volume2.13M
Average Volume (3M)210.00K
Market Cap
HK$337.46M
Enterprise ValueHK$295.35M
Total Cash (Recent Filing)HK$232.63M
Total Debt (Recent Filing)HK$227.90M
Price to Earnings (P/E)7.3
Beta0.32
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.12%
Share Statistics
EPS (TTM)0.01
Shares Outstanding2,032,890,600
10 Day Avg. Volume85,200
30 Day Avg. Volume210,000
Financial Highlights & Ratios
PEG Ratio-19.24
Price to Book (P/B)0.59
Price to Sales (P/S)0.14
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Model & R&D FocusSinco's business combines R&D, manufacturing and multi-channel sales to hospitals, pharmacies and partners, plus government contracts. That diversified model reduces customer concentration and supports steady product uptake, enabling durable revenue streams and sustained investment in innovation.
Strong Equity Position With Manageable LeverageA consistently increasing equity base and manageable debt-to-equity provide financial flexibility for capex, R&D and regulatory investments. This stronger capital foundation lowers solvency risk, supports long-term strategy execution and cushions operational volatility over the coming months.
Resilient Gross And Operating MarginsStable gross margins and resilient EBIT/EBITDA indicate durable cost structure and pricing ability in core products. That margin stability supports internal cash generation, funds continued R&D and manufacturing scale, and helps absorb periodic revenue volatility without immediate structural margin erosion.
Bears Say
Recent Revenue ContractionA near-term revenue decline of ~16.5% reflects weakening top-line momentum that, if persistent, can impair long-term R&D funding, commercial investments and market share. Sustained revenue contraction would pressure margins and limit the company's ability to execute strategic growth initiatives over 2-6 months.
Weak And Inconsistent Cash GenerationDeclining free cash flow and volatile operating cash flow reduce internal funding for operations, R&D and working capital. Over time this increases reliance on external financing, constrains strategic flexibility, and raises execution risk for product launches or regulatory commitments.
Equity Ratio Volatility Implies Balance Sheet UncertaintyVolatility in the equity ratio signals shifts in asset or liability structure and possible working capital or capital allocation swings. That instability raises uncertainty about leverage trends and could complicate funding plans or investor confidence during periods of revenue or cash-flow stress.
Sinco Pharmaceuticals Holdings Ltd. News
6833 FAQ
What was Sinco Pharmaceuticals Holdings Ltd.’s price range in the past 12 months?
Sinco Pharmaceuticals Holdings Ltd. lowest stock price was HK$0.15 and its highest was HK$0.28 in the past 12 months.
What is Sinco Pharmaceuticals Holdings Ltd.’s market cap?
Sinco Pharmaceuticals Holdings Ltd.’s market cap is HK$337.46M.
When is Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date?
Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date is Apr 01, 2026 which is in 36 days.
How were Sinco Pharmaceuticals Holdings Ltd.’s earnings last quarter?
Sinco Pharmaceuticals Holdings Ltd. released its earnings results on Aug 27, 2025. The company reported HK$0.013 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.013.
Is Sinco Pharmaceuticals Holdings Ltd. overvalued?
According to Wall Street analysts Sinco Pharmaceuticals Holdings Ltd.’s price is currently Overvalued.
Does Sinco Pharmaceuticals Holdings Ltd. pay dividends?
Sinco Pharmaceuticals Holdings Ltd. pays a Annually dividend of HK$0.002 which represents an annual dividend yield of 1.12%. See more information on Sinco Pharmaceuticals Holdings Ltd. dividends here
What is Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate?
Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinco Pharmaceuticals Holdings Ltd. have?
Sinco Pharmaceuticals Holdings Ltd. has 2,032,890,600 shares outstanding.
What happened to Sinco Pharmaceuticals Holdings Ltd.’s price movement after its last earnings report?
Sinco Pharmaceuticals Holdings Ltd. reported an EPS of HK$0.013 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.82%.
Which hedge fund is a major shareholder of Sinco Pharmaceuticals Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:6833
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinco Pharmaceuticals Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.16%
12-Months-Change
Fundamentals
Return on Equity
6.37%
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.
Technical Analysis
Wanka Online, Inc.
―
Asiaray Media Group Ltd.
―
SEEC Media Group Limited
―
Netjoy Holdings Limited
―
Rego Interactive Co., Ltd.
―